Spirogen, a member of the AstraZeneca group, specializes in the development of potent and flexible Antibody Drug Conjugates (ADCs) using its proprietary Pyrrolobenzodiazepine (PBD) technology. The company focuses on creating high-potency cytotoxic drug warheads that are highly specific to tumors and can be internalized effectively. These PBD payloads have been clinically validated in multiple partnered programs, demonstrating their efficacy in targeting cancer cells, including cancer stem cells. Spirogen collaborates closely with licensors of its PBD ADC technology, providing expertise in selecting the optimal payload for specific applications. The company operates in the biopharmaceutical market, serving clients such as pharmaceutical companies and research institutions. Its business model revolves around licensing its technology and forming strategic partnerships to enable the development and commercialization of ADCs. Spirogen generates revenue through licensing agreements and collaborative partnerships with major pharmaceutical companies, including AstraZeneca, MedImmune, Regeneron Pharmaceuticals, Mitsubishi Tanabe Pharma, and GamaMabs Pharma.

Keywords: Antibody Drug Conjugates, PBD Technology, Cytotoxic Warheads, Tumor Specificity, Cancer Treatment, Biopharmaceutical, Licensing, Strategic Partnerships, Clinical Validation, AstraZeneca.